HC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM)

Posted by Stephan Jacobs on Mar 28th, 2025

IceCure Medical (NASDAQ:ICCM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $2.50 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 126.24% from the company’s previous close.

IceCure Medical Price Performance

IceCure Medical stock opened at $1.11 on Friday. The business’s 50-day simple moving average is $1.32 and its 200 day simple moving average is $0.98. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The stock has a market cap of $61.33 million, a price-to-earnings ratio of -3.81 and a beta of 0.37. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.66.

IceCure Medical (NASDAQ:ICCM – Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.07 million. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. As a group, research analysts anticipate that IceCure Medical will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. XTX Topco Ltd raised its stake in shares of IceCure Medical Ltd (NASDAQ:ICCM – Free Report) by 123.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,866 shares of the company’s stock after buying an additional 32,555 shares during the quarter. XTX Topco Ltd owned about 0.11% of IceCure Medical worth $65,000 at the end of the most recent reporting period. 0.62% of the stock is owned by institutional investors and hedge funds.

About IceCure Medical

(Get Free Report)

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.